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Introduction: In light of recent research the efficacy of current advanced life support treatments has been 
questioned. Ventricular fibrillation refractory to standard therapy is a presentation which may benefit 
from an updated approach to management, with the 1-adrenoreceptor antagonist esmolol considered a 
therapy which may confer benefit. This systematic review and meta-analysis aimed to summarise the 
available evidence for esmolol in refractory ventricular fibrillation and identify if it may have any role in 
ACLS guidelines. 
 
Methods:  The Cochrane Library, MEDLINE, CINAHL and EMBASE were systematically reviewed, 
along with trial registries and the grey literature. Studies were included in the review and subsequent 
meta-analysis if they examined adult patients in cardiopulmonary arrest with ventricular fibrillation 
refractory to at least three attempts at defibrillation and one dose of adrenaline or anti-arrhythmic therapy, 
who subsequently received intravenous esmolol.  
 
Results:  2,617 results were obtained with 12 full-text articles reviewed for inclusion. Ultimately, two 
unique results fulfilled the inclusion criteria. A total of 66 patients were included in the meta-analysis, of 
whom 22 received esmolol. Esmolol appears to improve to survival to hospital admission (RR 2.63, 95% 
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CI 1.37-5.07, p=0.004), temporary (RR 2.34, 95% CI 1.09-5.02, p=0.03) and sustained ROSC (RR 2.63, 
95% CI 1.37-5.07, p=0.004) and favourable neurological status at hospital discharge (RR 3.44, 95% CI 
1.11-10.67, p=0.03). The use of esmolol also appeared to likely confer a benefit in survival to hospital 
discharge (RR 2.82, 95% CI 1.01-7.93, p=0.05). However, significant bias was observed across all 
outcomes and overall these results were considered to be of low to very low certainty.  
 
Conclusion: The use of esmolol in refractory ventricular fibrillation appears to improve survival to 
hospital admission, temporary and sustained ROSC and neurological status at hospital discharge, but not 
survival to hospital discharge. However, these results should be interpreted with caution in light of the 
limitations of included studies and the subsequent impact of these limitations on the outcomes included in 
the meta-analysis. Further high-quality, prospective research is required prior to recommending esmolol 
for use in refractory ventricular fibrillation. 
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Introduction 
Sudden Cardiopulmonary Arrest (SCA) is the cessation of spontaneous respirations and cardiac activity, 
resulting in a rapid loss of perfusion and without treatment, death (1, 2). SCA frequently occurs in an 
emergency setting, whether out-of-hospital (OHSCA) or in the emergency department, requiring 
intervention from pre-hospital and emergency clinicians (3). In the United Kingdom (UK) ambulance 
services attempt resuscitation in approximately 30,000 cases of OHSCA annually (4), in Canada 35,000 
(5), in Australia 15,000 (6) and in the United States of America (USA) 356,000 (7). Despite the extensive 
efforts of both pre-hospital and emergency clinicians, survival from OHSCA remains low at 5-12% 
depending on geographic region (4-7). Survival and neurological status post-resuscitation in SCA and 
OHSCA is most heavily associated with the immediate provision of Basic Life Support (BLS) 
interventions by bystanders or clinicians, including early chest compressions and defibrillation (8-10). 
However, some cases of SCA will not resolve with these initial measures.  
 
In cases of SCA unresponsive to BLS interventions, Advanced Cardiac Life Support (ACLS) is initiated. 
Traditionally, this has included the provision of advanced airway management in the form of endotracheal 
intubation or supraglottic airway placement as well as the commencement of pharmacological therapies 
such as epinephrine, amiodarone and lidocaine. However, recent research such as AIRWAYS-2 (11), 
PARAMEDIC-2 (12) and ALPS (13), amongst others (14, 15), has raised questions regarding the efficacy 
of current recommended ACLS therapies. Given the plethora of underlying physiological states which 
may precipitate SCA (2), an individualised approach to the management of SCA has been advocated, as 
opposed to the didactic approach recommended by many ACLS algorithms. Ventricular Fibrillation (VF) 
refractory to initial defibrillation attempts is one such presentation of SCA which is hypothesised to likely 
benefit from a unique, tailored management strategy.  
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VF is a commonly reported arrhythmia in SCA and OHSCA (16, 17) and is generally classed as 
refractory when unresponsive to at least three consecutive attempts at defibrillation and initial anti-
arrhythmic therapy (18-20), although some literature suggests 10-minutes of consecutive resuscitation 
without conversion from VF refractory (21, 22). Refractory VF (rVF) results in a large surge of 
endogenous sympathetic hormones (epinephrine and norepinephrine) (23, 24), which is compounded by 
the administration of high-dose adrenaline in ACLS care. The excessive levels of circulating 
catecholamines cause a dramatic increase in myocardial oxygen demand through positive chronotropy 
and inotropy (25, 26), as well as over stimulation of -adrenoreceptors, particularly 1-adrenoreceptors 
(25-26). Excessive activation of 1-adrenoreceptors causes an increase in calcium influx into myocardial 
cells (27). This action, in conjunction with a continually rising myocardial oxygen demand, conspire to 
reduce the likelihood of successful attempts at defibrillation (23-24, 28). The use of Double Sequential 
Defibrillation (DSD) or intravenous -antagonists has been hypothesised to improve the likelihood of 
successful defibrillation in rVF (19, 29-33). However, a recent meta-analysis found no evidence of benefit 
for DSD in rVF (34) and a meta-analysis performed in 2012 found insufficient evidence to provide firm 
recommendations regarding -antagonist use, although a trend towards benefit was observed (33).  
 
Since the completion of the meta-analysis investigating -antagonists (33) esmolol has emerged as the -
antagonist potentially most appropriate for use in SCA, owing to its selective 1-adrenoreceptor 
antagonism and rapid onset of action (33, 35).  In animal models of SCA the use of esmolol has been 
shown to blunt the effects of the sympathetic surge in rVF, resulting in improved rates of resuscitation 
(36-37), reduced energy requirements for defibrillation (36-37), improved cardiovascular stability post-
resuscitation (37-38) and better short-term survival (37-38). However, definitive guidance on the use of 
esmolol in human SCA is lacking. This systematic review and meta-analysis aimed to summarise the 
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available evidence for the use of esmolol in cases of rVF and identify if it may have a role in ACLS 
guidelines.  
 
Objectives 
This systematic review and meta-analysis aimed to determine whether the addition of intravenous 
esmolol, as an initial bolus dose with subsequent infusion, to standard ACLS care provided to patients in 
rVF: 
 Impacts patient survival to hospital admission  
 Impacts patient survival to hospital discharge  
 Impacts patient neurological status at hospital discharge  
 Influences the rate of return of spontaneous circulation in this group  
Methods 
This systematic review and meta-analysis were performed and reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guideline (Supplementary File).   
Study Types for Inclusion  
Randomised controlled trials, non-randomised controlled trials and cohort studies were preferentially 
sought for inclusion in this review and meta-analysis. However, given the limited results fulfilling these 
criteria case-control series were also subsequently considered for inclusion in this review.  
Population Examined  
Adult patients (18 years of age or over) in cardiopulmonary arrest in the out-of-hospital or emergency 
setting with a presenting rhythm of ventricular fibrillation refractory to standard ACLS therapy, defined 
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as a minimum of three attempts at defibrillation and at least one dose of intravenous epinephrine and/or 
anti-arrhythmic therapy.  
Intervention and Comparison  
The intervention examined was intravenous esmolol at an initial bolus dose of 500mcg/kg, followed by an 
infusion of up to 100mcg/kg/min. Patients receiving this therapy were compared against patients who did 
not receive intravenous esmolol as part of their ongoing resuscitative efforts and had received a minimum 
of three attempts at defibrillation and at least one dose of intravenous adrenaline or anti-arrhythmic 
therapy.  
Primary Outcome Measure  
Patient survival to hospital admission.  
Secondary Outcome Measures  
Return of Spontaneous Circulation, patient survival to hospital discharge and patient neurological status 
at hospital discharge (measured with the Cerebral Performance Category Score, with scores of one or two 
considered favourable).  
Figure 1: Cerebral Performance Categories Scale (39) 
CPC 1 Good cerebral performance: conscious, alert, able to work and may have mild neurologic or 
psychologic deficit  
CPC 2 Moderate cerebral disability: conscious, sufficient cerebral function for independent 
activities of daily life and able to work in sheltered environment  
CPC 3 Severe cerebral disability: conscious, dependent on others for daily support because of 
impaired brain function 
CPC 4 Coma or vegetative state: any degree of coma without the presence of all brain death criteria  
CPC 5 Brain death: apnoea, areflexia, EEG silence 
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Search Strategies (Supplementary File) 
In order to ensure potential evidence was obtained from both the fields of emergency and pre-hospital 
medicine a number of electronic databases were searched from their date of inception until November 
2018, including The Cochrane Library, MEDLINE, EMBASE and CINAHL (Supplemental File). Search 
strategies were not limited by language, publication status or date. The ISRCTN Registry of Controlled 
Trials, the WHO International Clinical Trials Registry Platform, Health Canada’s Clinical Trials Registry 
and the United States National Library of Medicine Clinical Trial Registry were also searched for 
ongoing clinical trials into the use of esmolol in rVF. Scopus and EMBASE were utilised to scan 
conference proceedings for potential unpublished literature or literature currently under review. Google 
Scholar and Open Grey Europe were utilised to scan for any further grey literature related to esmolol in 
rVF. Citations from retrieved results were also inspected for results not obtained utilising the search 
strategy or in the analysis of the grey literature.  
Selection of Studies  
In determining the eligibility of retrieved studies for inclusion in this systematic review and meta-
analysis, both authors performed a preliminary analysis of the title and abstract of each retrieved result 
from the electronic databases and grey literature. The pre-defined inclusion criteria were applied to the 
retrieved results and where doubt existed, the full-text was retrieved for assessment of possible inclusion. 
If further uncertainty existed, an agreement was reached between authors.  
Assessment of Methodological Quality  
The assessment of methodological quality was performed by both authors, blinded to the others’ verdict, 
employing previously validated checklists for assessment of study rigor.  
 Randomised Controlled Trials were assessed using the CASP Checklist for Randomised 
Controlled Trials (40) 
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 Cohort Studies were assessed using the CASP Checklist for Cohort Studies (41) 
 Case-Control Series were assessed using the Joanna Briggs Institute Checklist for Case-Control 
Series (42) 
 Data Extraction  
Both authors extracted data from results meeting the inclusion criteria utilising a standardised data 
extraction form. Data was pre-defined for extraction and is summarised in Table 1. Where uncertainty 
existed regarding any data extracted from eligible results, the data extraction performed by each author 
were compared to ensure complete analysis. If data was unclear, lead authors from eligible studies were 
contacted for clarification.  
 
 
 
 
 
 
 
 
 
 
 
Table 1: Data to be Extracted 
Patient Population  Age  
 Sex 
 Co-morbidities present  
Cardiac Arrest 
Characteristics 
 Witnessed compared with 
Unwitnessed  
 Bystander CPR provided  
 Suspected aetiology 
Standard Therapy 
Provided 
 Defibrillation  
 Epinephrine  
 Amiodarone  
 Lidocaine  
 Sodium Bicarbonate  
 Other non-specified  
Intervention 
Characteristics 
 Timing of Esmolol  
 Dosage of Esmolol 
Outcome Measures  Measures utilised 
 Timing of outcome 
assessment 
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Assessment of Risk of Bias  
Both authors assessed the risk of bias at the study level utilising the Cochrane Collaboration’s Tool for 
Assessing Risk of Bias in randomised studies and using the ROBINS-I Tool in non-randomised studies. 
When assessing the risk of bias across outcomes and the certainty of evidence the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) approach was utilised. Where 
uncertainty existed agreement was reached between authors.  
Synthesis of Results  
Data collected was placed in a single spreadsheet for ease of access, with results combined using the 
RevMan 5.3 Software and presented in a GRADE Evidence Profile table graciously provided by 
GRADEpro on a student license. A random-effects model of meta-analysis was utilised, with a risk-ratio 
chosen for the presentation of results. A risk-ratio was chosen as although the overall survival from 
OHSCA is 5-12%, survival in cases of VF is commonly reported as greater than 10% (42). Outcomes 
which occur at a rate of 10% or higher are often exaggerated by odds-ratios, with risk-ratios also easier to 
apply to clinical practice (43). Heterogeneity was assessed utilising the I2 statistic.  
 
Results 
Study Selection  
The search strategies retrieved 17 results from The Cochrane Library, 24 results from CINAHL, 362 
results from MEDLINE and 2,200 results from EMBASE. After removal of duplicates and screening of 
abstracts 12 full-text articles were assessed for inclusion. Two full-text articles ultimately fulfilled the 
pre-defined inclusion criteria. Searching the grey literature, unpublished literature and conference 
abstracts yielded two abstracts potentially relevant to this systematic review and meta-analysis, however, 
Armour and Baranowski. Esmolol systematic review. https://doi.org/10.32378/ijp.v4i2.177  
 10 
no contact information was provided for these abstracts and the results appeared to primarily relate to 
clinical settings outside SCA.  
Figure 2: Study Selection Flow 
 
 
 
 
 
 
 
 
Study Characteristics  
No randomised or non-randomised controlled trials were identified in the systematic review, with the two 
studies identified both retrospective cohort studies. One study was conducted in the USA by Driver et al 
(44), whilst the other was conducted in South Korea by Lee et al (45). The combined studies included a 
total of 66 patients, of whom 22 received esmolol and 44 did not. Patients were overwhelmingly male 
(n=57/66) with the median age ranging from 52 to 58 between treatment groups. The pre-morbid state of 
patients was poorly described by both authors, with Driver et al providing information regarding the pre-
morbid state of only those patients receiving esmolol and Lee et al providing no information (44, 45).  
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The majority of SCAs were witnessed events (n=52/66) and were largely the result of cardiac pathology 
(n=42/66). Bystander chest compressions (CC) were provided in 47 cases (71%), a rate higher than the 
North American average of 46% (46). In Driver et al, interventional patients received a median of 6.5 
attempts at defibrillation (IQR 5-9.5) compared with control patients who had a median of 7 attempts 
(IQR 5-8) (44). This was contrasted in Lee et al, where patients receiving esmolol had a median of 6 
attempts at defibrillation (IQR 6-8.75), whilst control patients received a median of 5 attempts (IQR 5-
6.5) (45).  
 
 
Table 2: Study Characteristics & Retrieved Data 
Values reported as Medians with Interquartile Ranges, where appropriate 
Study Driver et al 2014 44 Lee et al 2016 45 
Group Esmolol No Esmolol Esmolol No Esmolol 
Age 54.5 (47-59) 56 (48-66) 58 (43.5-72) 52 (43.5-64.5) 
Male (%)  6 (100) 18 (95) 14 (87.5) 19 (76) 
Witnessed (%) 5 (83) 16 (84) 14 (87.5) 17 (68) 
Bystander CPR Provided 
(%) 
3 (75) 14 (78) 11 (69) 16 (64) 
Suspected Cardiac Aetiology 
(%)  
2 (33%) Not Described 15 (94) 23 (92) 
Defibrillation 6.5 (5-9.5) 7 (5-8) 6 (6-8.75) 5 (5-6.5) 
Epinephrine (mg) 6 (5-7.75) 6 (5-7) 6 (3.3-9) 6 (5-8) 
Amiodarone (mg) 375 (300-450) 450 (300-450) 450 (300-450) 300 (300-450) 
Sodium Bicarbonate (mEq)  225 (200-
287.5) 
150 (100-250) 0 (0-40) 0 (0-160) 
Timing of Esmolol (minutes) 46 (37.75-
57.5) 
N/A Not Described N/A 
Esmolol/Infusion Dose 
(mcg/kg) 
500/75 N/A Not Described N/A 
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Quantitative Data Synthesis  
Both retrieved studies reported on the primary outcome of survival to hospital admission, as well as the 
secondary outcome of return of spontaneous circulation (ROSC). However, ROSC was delineated by both 
studies into temporary (greater than 30 seconds but less than 20 minutes) and sustained ROSC (over 20 
minutes). Patient survival beyond hospital admission and neurological status post-SCA were assessed in 
both studies but at differing time points. Driver et al assessed patient survival and neurological status at 
the time of hospital discharge (44); however, Lee et al measured these outcomes at 30 days, three months 
and six months post-SCA (45). The authors of both studies were contacted in an attempt to amalgamate 
the raw patient data from both studies into an identical time point, however, the data was either 
unavailable or no response was received. Given that in Lee et al both survival and favourable neurological 
outcome remained unchanged between the three time points (45), these were used as an indicator of status 
at hospital discharge in an attempt to assess the potential effect of esmolol on long-term survival and 
neurological function post-SCA.  
 
The results of quantitative data synthesis are shown in Figure 2. Esmolol was seen to provide a benefit 
when compared against standard ACLS care in the primary outcome of survival to hospital admission 
(RR 2.63, 95% CI 1.37-5.07, p=0.004), as well as in the secondary outcomes of temporary (RR 2.34, 95% 
CI 1.09-5.02, p=0.03) and sustained ROSC (RR 2.63, 95% CI 1.37-5.07, p=0.004) and favourable 
neurological status at hospital discharge (RR 3.44, 95% CI 1.11-10.67, p=0.03). The use of esmolol 
appeared to likely confer benefit in survival to hospital discharge (RR 2.82, 95% CI 1.01-7.93, p=0.05). It 
should be noted that in Driver et al, the only outcome measure reaching statistical significance was 
favourable neurological outcome at hospital discharge (RR 4.75, 95% CI 1.02-22.06, p=0.04) (44). 
Significant heterogeneity was observed in the computation of temporary ROSC, with otherwise no 
heterogeneity observed. Without access to raw patient data, no subgroup analyses were performed. 
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Figure 3: Forest Plot of Outcome Measures 
 
 
 
 
 
 
 
 
 
 
 
 
Quality Assessment and Risk of Bias (Supplementary File) 
 
Both retrieved studies were considered to be of moderate methodological quality and at a significant risk 
of bias. It is unclear whether outcome assessors were blinded to treatment allocation in the assessment of 
ordinal variables. Whilst this was unlikely to influence the assessment of dichotomous outcomes (survival 
and ROSC), this could potentially influence the assessment of CPC score, with this methodological flaw 
placing both authors at moderate risk in the measurement of outcomes and detracting the level of 
a 
b 
c 
d 
e 
a) Survival to Hospital Admission b) Sustained ROSC c) Temporary ROSC d) Survival to Hospital Discharge e) Favourable 
Neurological Status at Hospital Discharge 
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confidence in the assessment of this outcome. In Driver et al (44), this was further compounded by the 
potential for inaccuracy in the measurement of outcomes, as the CPC score assessing neurological status 
was estimated based on notes from other clinicians at the time of hospital discharge. Four patients were 
excluded from the research performed by Driver et al (44) because of missing data, with the study 
subsequently considered at a moderate risk of bias because of this. The administration of esmolol in 
Driver et al (44) also appears to have been at physician discretion, leading to potential and likely 
significant sampling bias.  
 
However, the assessment of both studies at significant risk of bias was primarily driven by the influence 
of confounding on the results obtained, which also affected the certainty of all outcome measures within 
the meta-analysis. Lee et al (45) failed to identify confounders present in their research, most notably pre-
morbid state and post-ROSC therapies, which are both known predictors of patient status post-SCA (47, 
48). Although Driver et al (44) did identify the majority of confounders potentially present in their 
research, however, neither group of authors modified the design of their research to minimise the 
influence of known or unknown confounders on the outcomes observed, with no multi-variate analyses 
performed (44, 45). 
 
GRADE Evaluation (Available in Supplementary Files)  
All outcomes were considered to suffer from significant imprecision, with wide confidence intervals 
reported. Significant heterogeneity was observed in the computation of temporary ROSC, leading to this 
result being considered of very low certainty. Considering the dichotomous outcomes were unlikely to be 
affected by knowledge of treatment group, these were considered only at serious risk of bias given the 
failure to account for residual confounders. However, because evaluation of CPC score may potentially be 
influenced by knowledge of treatment group, this result was considered of very low certainty.  
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Discussion 
A systematic review of the literature identified just two retrospective cohort studies examining the use of 
esmolol in rVF in human subjects. In completing a meta-analysis of the results from these studies, 
esmolol was found to improve patient survival to hospital admission, rates of temporary and sustained 
ROSC, favourable neurological status at hospital discharge and potentially survival to hospital discharge. 
However, it is important to interpret these results with a degree of caution, as the certainty in this 
evidence is of low to very low (49). No randomised, nor controlled, studies were identified, with both 
studies suffering from issues inherent in retrospective analyses including small sample sizes, 
methodological issues and significant risk of bias. Most concerning was the possible influence of 
confounding in both studies. Factors such as pre-morbid state, provision of bystander CC, length of SCA 
and timeliness of access to definitive care post-resuscitation have all been identified as influencing patient 
outcomes post-SCA (47). Although Driver et al (44) acknowledge the potential role these factors may 
have had on their outcomes, neither research group attempted to quantify the impact these factors may 
have had on outcomes in the design of their research or through the performance of multivariate analyses 
(44, 45), which ultimately affected the level of confidence within each outcome assessed.  
 
Equally important to note is the potential role pre-hospital care and sampling bias played in the results 
obtained. In Driver et al, no difference was noted in total CC time between the intervention and control 
groups, despite a prolonged pre-hospital phase of care in the control group (44). This is consistent with 
the finding that patients who were expeditiously transported to the emergency department in rVF 
subsequently received prolonged resuscitative efforts in the emergency department, whilst those who 
arrived in the emergency department later in their SCA received shorter resuscitation times in the 
emergency department (44). Given that the administration of esmolol appears to have been at physician 
discretion it is possible patients with shorter pre-hospital phases of care received more aggressive 
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resuscitative measures, such as esmolol, as they were perceived to have better prognoses than those with 
protracted pre-hospital phases of care. This phenomenon was also observed by Lee et al (45), who found 
that patients with shorter pre-hospital phases of care experienced an improved likelihood of sustained 
ROSC (p=0.02), despite similar total CC times between treatment and control groups. This, in itself, may 
result in this meta-analysis over-estimating the true benefit of esmolol in routine clinical practice as 
patients with perceived poorer prognoses may not have received esmolol based on this perception alone.  
 
Lee et al (45) did not report on time taken to the administration of esmolol, however, the research 
performed by Driver et al (44) revealed substantial variability in the time taken to administration of 
esmolol. As previously stated, VF is considered refractory after at least three consecutive attempts at 
defibrillation and at least one dose of adrenaline or anti-arrhythmic therapy (18-20). Based on 
resuscitation guidelines, the earliest VF could be considered refractory is after six minutes of 
resuscitation, although in true clinical practice there may be a delay dependent on available resources. 
Despite this, the median time to administration of esmolol in Driver et al was 24 minutes after arrival in 
the emergency department (IQR 18.5-34), or 46 minutes after the initial SCA (IQR 37.7-57.5) (44). By 
this time, patients had already received a median of 6.5 attempts at defibrillation (IQR 4.75-10.75), 
indicating the administration of traditional therapy was prioritised over the administration of esmolol. 
This may also serve to mask the true benefit of esmolol, given the neurological damage associated with 
reduced cerebral perfusion pressures in prolonged resuscitation as well as the effect of increasing 
exogenous adrenaline administered throughout the resuscitative efforts which may hinder the antagonistic 
effects of esmolol.  
 
Although the administration of a potentially life-saving medication, esmolol, in the setting of SCA and 
OHSCA could be considered low-risk, neither paper examined nor reported on adverse outcomes 
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associated with the use of esmolol in rVF. In animal models, the use of intra-arrest esmolol for rVF was 
shown to have no deleterious effects on post-resuscitation cardiovascular stability (37, 38). However, the 
potential for adverse events from the antagonism of 1-adrenoreceptors in the post-resuscitation patient 
cannot be discounted without a strong evidence base in humans. Institutions already employing the use of 
esmolol in the management of rVF should continue to be diligent in assessing for adverse effects 
secondary to the use of esmolol.  
 
Conclusion 
This systematic review and meta-analysis assessing the role of esmolol in the management of refractory 
ventricular fibrillation suggests that the use of esmolol is associated with improved survival to hospital 
admission, increased temporary and sustained ROSC and improved favourable neurological status at 
hospital discharge, and likely improved survival to hospital discharge. However, the conclusions of this 
meta-analysis are considerably limited by the significant risk of bias present in both studies, issues in 
methodological quality and small sample sizes as well as a lack of analysis regarding the safety of 
esmolol in the setting of cardiopulmonary arrest. With the strength of evidence of the retrieved results 
considered low to very low, high-quality, prospective research, preferably in the form of co-ordinated 
randomised controlled trials between pre-hospital and emergency clinicians, is urgently needed to assess 
the true impact of esmolol in the setting of refractory ventricular fibrillation before esmolol can be 
recommended for use in routine clinical  practice.  
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